Anvi Gadani, MD
Neurology · Washington, DCNPI 1083061329
Payments from drug & device makers
What this record shows
This record is dominated by grants: $24,000 of the $32,712 with a category attached, or 73.4%. Medtronic accounts for 78.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $21,921 and has fallen 93.5% since, to $1,430 in 2025.
Across 327 payments — averaging $100.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- AbbVie$1K
- Acadia Pharmaceuticals Inc$720
- MDD US Operations, LLC$595
- Teva Pharmaceuticals USA, Inc.$566
- Lilly USA, LLC$499
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$170%
- Grants$24,00073%
- Travel & lodging$1,0553%
- Food & beverage$7,29822%
- Education$3421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 30 | $25,595 |
| AbbVie(2 entities) | 61 | $1,252 |
| Acadia Pharmaceuticals Inc | 54 | $720 |
| MDD US Operations, LLC | 20 | $595 |
| Teva Pharmaceuticals USA, Inc. | 14 | $566 |
| Lilly USA, LLC | 19 | $499 |
| Kyowa Kirin, Inc. | 20 | $423 |
| Eisai Inc. | 12 | $401 |
| Neurocrine Biosciences, Inc. | 10 | $323 |
| Supernus Pharmaceuticals, Inc. | 2 | $280 |
| Acorda Therapeutics, Inc | 11 | $264 |
| Amneal Pharmaceuticals LLC | 12 | $250 |
| AstraZeneca(2 entities) | 8 | $221 |
| Adamas Pharmaceuticals, Inc. | 11 | $205 |
| Merz Pharmaceuticals, LLC | 7 | $196 |
| Boston Scientific | 4 | $178 |
| Otsuka America Pharmaceutical, Inc. | 5 | $123 |
| Biogen | 6 | $114 |
| Novartis | 3 | $91 |
| Revance Therapeutics, Inc. | 2 | $81 |
| Avion Pharmaceuticals | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 3 | $59 |
| Bristol Myers Squibb | 3 | $58 |
| Philips North America LLC | 2 | $53 |
| Sanofi | 1 | $35 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| TG Therapeutics, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,712 in reported general payments places this provider in the 80th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 37 | $290,444 |
| RytaryCarbidopa/Levodopa | 32 | $65,367 |
| NourianzIstradefylline | 18 | $57,265 |
| HorizantGabapentin Enacarbil | 11 | $26,488 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $15,379 |
| Rasagiline Mesylate | 26 | $5,179 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 89 | $2,337 |
| Pregabalin | 16 | $1,960 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 35 | $1,506 |
| Quetiapine Fumarate | 38 | $1,382 |
| Donepezil Hcl | 116 | $1,245 |
| Gabapentin | 53 | $1,083 |
| Escitalopram Oxalate | 38 | $646 |
| Memantine Hcl | 16 | $404 |
| Clonazepam | 20 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $720 | $290,44437 claims |
| Amneal Pharmaceuticals LLCRytary | $250 | $65,36732 claims |
| Kyowa Kirin, Inc.Nourianz | $423 | $57,26518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.